Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots.

This was the stock's third consecutive day of losses.

ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...

Hikma Pharmaceuticals PLC hit a new 52-week high, surpassing its previous peak of £23.14, which the company achieved on ...

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

The abstract, Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tumors ( Perez, ...

The North American robotics market demonstrated minor overall growth in 2024, reflecting resilience and adaptability as ...

In a report released today, Elyse Shapiro from Canaccord Genuity maintained a Buy rating on Mayne Pharma Group (MAYNF – Research Report), with ...

Bain's latest acquisition follows a string of hefty investments the private equity firm has made in Japan in recent months.

As a market leader, Rocket Companies rebranding comes in the foreground of several court battles and fluctuating earnings ...